- Home
- CIK vs DERM Comparison
CIK vs DERM Comparison
Compare CIK & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- DERM
- Stock Information
- Founded
- CIK 1987
- DERM 2014
- Country
- CIK United States
- DERM United States
- Employees
- CIK N/A
- DERM N/A
- Industry
- CIK Finance/Investors Services
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- CIK Finance
- DERM Health Care
- Exchange
- CIK Nasdaq
- DERM Nasdaq
- Market Cap
- CIK 156.6M
- DERM 174.7M
- IPO Year
- CIK N/A
- DERM 2021
- Fundamental
- Price
- CIK $2.90
- DERM $6.45
- Analyst Decision
- CIK
- DERM Strong Buy
- Analyst Count
- CIK 0
- DERM 2
- Target Price
- CIK N/A
- DERM $10.00
- AVG Volume (30 Days)
- CIK 115.4K
- DERM 79.2K
- Earning Date
- CIK 01-01-0001
- DERM 05-20-2025
- Dividend Yield
- CIK 9.03%
- DERM N/A
- EPS Growth
- CIK N/A
- DERM N/A
- EPS
- CIK N/A
- DERM N/A
- Revenue
- CIK N/A
- DERM $56,134,000.00
- Revenue This Year
- CIK N/A
- DERM $29.83
- Revenue Next Year
- CIK N/A
- DERM $54.88
- P/E Ratio
- CIK N/A
- DERM N/A
- Revenue Growth
- CIK N/A
- DERM N/A
- 52 Week Low
- CIK $2.50
- DERM $3.20
- 52 Week High
- CIK $3.19
- DERM $7.84
- Technical
- Relative Strength Index (RSI)
- CIK 61.50
- DERM 46.20
- Support Level
- CIK $2.81
- DERM $6.11
- Resistance Level
- CIK $2.91
- DERM $7.10
- Average True Range (ATR)
- CIK 0.03
- DERM 0.43
- MACD
- CIK 0.01
- DERM -0.12
- Stochastic Oscillator
- CIK 89.29
- DERM 21.91
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations, and individuals.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.